Alzheimer’s and Lewy Body Dementia Updates, New Antibody Trials, and the “Ghost Cholesterol"

Alzheimer’s and Lewy Body Dementia Updates, New Antibody Trials, and the “Ghost Cholesterol"

Season eight of Village’s Vitality Life (formerly Open Forum in The Villages, Florida) features a conversation between host Mike Roth and Dr. Craig Curtis about Alzheimer’s disease, Lewy body dementia, and related research and clinical trials relevant to seniors.

Chapters:
- Podcast season focus and listener-supported format
- Lewy body dementia: current diagnosis is clinical due to lack of reliable blood test or scan
- Differences between Alzheimer’s and Lewy body dementia: different protein build-ups (amyloid vs. alpha-synuclein) and typical symptom patterns (memory-first vs. emotional changes then memory)
- Parkinson’s connection: same alpha-synuclein protein; spinal fluid “seed amplification assay” now reliable for Parkinson’s and may later apply to Lewy body dementia
- Alzheimer’s research direction: new re-engineered antibody tritinamab described as potentially 10–15x safer, faster amyloid removal (3–4 months vs. 12–18 months), and currently in final-phase clinical trials started late December 2025 with ~1,500 participants treated for 18 months
- Prevention trial plans: upcoming double-blind study screening ages 55–80 without cognitive concerns using blood testing and PET confirmation; medicine vs. placebo over 18 months
- Current approved Alzheimer’s antibodies: remove amyloid and slow progression ~30% but carry significant risks of brain swelling and brain bleeding
- Vascular focus: discussion of lipoprotein(a) “Lp(a)” as genetically linked “ghost cholesterol,” a major risk factor for cardiovascular, cerebrovascular, and peripheral vascular disease; diet and statins do not significantly reduce it
- New Lp(a) pill research: reported ~85% reduction in a small ~500-person study; launching a large 26-country outcomes trial (13,000 participants; ~100,000 screened) with five-year follow-up to see if lowering Lp(a) reduces major adverse cardiac events; trial enrolls higher-risk individuals to ensure sufficient event rates
- Link to Alzheimer’s: about 20–25% of Alzheimer’s patients have some vascular disease in the brain that may worsen symptoms; improving vascular health may help slow neurodegenerative disease progression
- Adjunct/alternative topics: favorable view of hyperbaric oxygen based on science and case studies but lack of large double-blind trials; stem cells and peptides described as promising but lacking large randomized double-blind evidence; platelet-rich plasma discussed as having studies suggesting limited benefit vs. placebo
- GLP-1 drugs and Alzheimer’s: recent study reported no statistically significant benefit over ~2 years, though biomarkers (tau/amyloid) trended in the right direction; more biomarker data expected at a March meeting in Copenhagen
- Local resources and participation: contact information provided for K2 Medical Research in Lady Lake, Florida (phone 352-500-5252; website k2medicalresearch.com); expectation of 6–7 new studies this year and mention of single-overnight phase 1 studies currently for Alzheimer’s and Parkinson’s
- Episode close: next episode release schedule, supporter acknowledgments, contact methods (email, website fan mail), and copyright notice

00:00 Welcome to Season 8 + What This Podcast Covers
00:43 Meet Dr. Craig Curtis: Today’s Focus on Alzheimer’s & Brain Heal

Season 8 Introduction

Transcript

Speaker: 0:28

Welcome to Season eight of Village's Vitality Life, senior's Life Unscripted. Our podcast used to be called Open Forum in The Villages, Florida. In this new season, we talk to leaders of clubs and interesting folks who live in and around The Villages. We also talk to people who have information vital to seniors. You'll get perspectives of what is happening in and around The Villages, Florida. In addition, in this new season, we will add more information for all seniors. We are a listener supported podcast.

Mike Roth: 0:59

This is Mike Roth on Open Forum in The Villages, Florida. I'm here today with Dr. Craig Curtis. Thanks for joining me, Craig.

Dr. Craig Curtis: 1:06

Thank you for having me, Mike.

Mike Roth: 1:08

Today we're gonna be talking about Alzheimer's diseases and maybe a few other brain diseases

Dr. Craig Curtis: 1:13

sounds good. Looking forward to it.

Mike Roth: 1:14

I heard you're working on Lewy body as well.

Dr. Craig Curtis: 1:17

There have been some recent advances in studying Lewy body dementia and in detecting Lewy body dementia, so that's allowing us now to at least move into the field of Lewy body dementia and looking at medications that might help someday.

Mike Roth: 1:32

How does Lewy body dementia get diagnosed?

Dr. Craig Curtis: 1:36

So currently it's a clinical diagnosis. So if you think about a disease, whether it's diabetes or whether it's an illness such as Lewy body dementia, you have Two main ways. You can either use diagnostic testing such as in diabetes, we would actually look at someone's blood sugar or potentially check their hemoglobin A1C, which can tell us what their blood sugars have been running, and then we can combine that with symptoms. Such as frequent urination or frequent thirst, and we can say, yes, that person has diabetes. But what was critical was the diagnostic testing,

Mike Roth: 2:17

Right.

Dr. Craig Curtis: 2:18

When it comes to most neurological disorders, especially the neurodegenerative disorders. We are seriously, unfortunately, lacking in diagnostic tests. For example, in Alzheimer's disease, we now have a blood test.

Mike Roth: 2:34

Mm-hmm.

Dr. Craig Curtis: 2:34

We a PET scan

Mike Roth: 2:36

mm-hmm.

Dr. Craig Curtis: 2:37

That we can use to actually see the agents

Mike Roth: 2:40

amyloid

Dr. Craig Curtis: 2:41

Yeah, I didn't want to get that technical. Yes, that we can actually see amyloid, which we believe causes Alzheimer's disease. So combining that diagnostic test with the clinical symptoms of memory loss and forgetfulness and trouble finding words, we can make good diagnosis of Alzheimer's disease with high accuracy in the case of Lewy body dementia. It's much more difficult because we do not have a diagnostic test. All we can do is go by clinical symptoms.

Mike Roth: 3:12

Okay, what differentiates Lewy body from Alzheimer's?

Dr. Craig Curtis: 3:16

So it's caused by a completely different protein buildup. In Alzheimer's disease, there's a protein called amyloid that builds up leading to the death of brain cells. In the memory area of our brain. In Lewy body dementia, it's a buildup of a protein called alpha clin that builds up In the cortex, the outside part of the brain that damages initially, usually our emotional side of the brain. So we do tend to see emotional changes in patients with then go on to have memory problems later on. And they can be diagnosed with Lewy body dementia. But it's a disease where we diagnose looking at clinical symptoms and makes it very challenging. For example, in the old days, 20 years ago and beyond, even in Alzheimer's disease, even the best experts in the world only had around a 75% accuracy of diagnosing. Using just clinical symptoms. And it usually took an average of three to four years of symptoms to where they felt confident enough calling it something such as Alzheimer's dementia. But If that person were to ever go to autopsy, they were only accurate around 75% of the time. Yeah. And now we're in the high nineties. As far as accuracy,

Mike Roth: 4:31

That's because of the blood tests and the PET scans,

Dr. Craig Curtis: 4:34

blood tests, pet scans, et cetera. So correct in Alzheimer's dementia, but in Lewy body dementia, unfortunately we do not have a reliable scan. We do not have a reliable blood test. I will say in Parkinson's disease. Which is caused by the same bad protein that causes Lewy body dementia. But in Parkinson's disease, that protein builds up in the brainstem as opposed to the rest of the brain, the outside part of the brain. When it builds up in the brainstem, it leads to Parkinson's disease. That we can now test with spinal fluid reliably.

Mike Roth: 5:14

Oh, really?

Dr. Craig Curtis: 5:15

About a year ago now the University of Pennsylvania and the Michael J. Fox Foundation released the results of a study using What they call a seed amplification assay, which is a test that uses a few drops of spinal fluid, where they look for that alpha andin protein it's kind of like building a snowman. You know how you start with a small snowball and you roll it and it gets bigger and bigger To where it's then finally big enough that maybe somebody a half a mile away could see it. If you built a big enough snowball, well imagine the same thing in the spinal fluid. We're looking for seeds that are really, really tiny. What they've found out they need to do is take these seeds, combine them with millions of other seeds, essentially roll the snowball to where it gets big enough that we can detect it with modern equipment.

Mike Roth: 6:08

Okay, so that gives a. Good diagnostic tool in the case of Parkinson's,

Dr. Craig Curtis: 6:13

In the case of Parkinson's. Now that should work for Lewy body dementia as well because it is caused by the same protein. It's just that the studies have not been done yet. So those studies are we hope starting soon. And I think there are also some studies ongoing currently looking at that.

Mike Roth: 6:31

Okay, Dr. Curtis. Are there any changes in the direction of Alzheimer's research?

Dr. Craig Curtis: 6:36

There have been some very important studies that have started recently. One in particular that I'd like to highlight is with a new antibody called Tritinamab and they've re-engineered sort of the existing antibodies that we're using to treat Alzheimer's dementia and Alzheimer's disease, scientists have re-engineered that antibody and so it appears to be much more effective and much safer.

Mike Roth: 7:02

Oh, That's important.

Dr. Craig Curtis: 7:03

Yeah, can I explain?

Mike Roth: 7:04

Sure.

Dr. Craig Curtis: 7:05

So currently the antibodies that are on the market, the medications that slow Alzheimer's disease, they only slow Alzheimer's disease around 30% after 18 months. And they do have a pretty significant side effect, brain swelling and occasionally brain bleeding. And these new antibodies in particular, Tritinamab appears to be about 10 to 15 times safer. And remarkably removes the amyloid in about three to four months versus about one year to 18 months on the existing medications. So this is a really significant breakthrough. It's currently in clinical trials. The good news is we're in the final phase. That study began about a month ago in late December, 2025. And we'll enroll approximately 1500 people across the United States and in other countries. And we will treat those patients for about 18 months. And hopefully we'll see good results at the end. But that's really important. The safety factor we think it's gonna end up being the early reports show that it's about 10 times safer than the current medications on the market. And appears to be significantly faster, maybe 10 times faster as well.

Mike Roth: 8:27

Wow, That's great. Are they looking at that as a preventative as well?

Dr. Craig Curtis: 8:30

So in about two months we will start a very large prevention trial. we'll once again look for people between the ages of 55 and 80 who do not have any memory problems cognitive concerns, and we will test them with the blood test to see if that is positive. And if so, they can screen into the research study to see if the PET scan is positive for amyloid. And at that point the. Prevention study would begin and half the people will get the medicine, half the people will receive placebo and we'll follow them for 18 months and see if that slows down progression.

Mike Roth: 9:11

Okay. So that's gonna be a typical double blind study.

Dr. Craig Curtis: 9:13

It will be, yes. All these studies at this point are still double blind studies.

Mike Roth: 9:19

Mm-hmm. Are there any breakthroughs in the area of treatment for people who have been diagnosed with Alzheimer's?

Dr. Craig Curtis: 9:25

We currently have the two medications approved in the last couple of years that do remove amyloid, that do slow progression of the disease, approximately 30%. However, they come with about a 30% risk of brain bleeds and brain swelling. And so that's a, those are significant risks. We're still fortunate to have those medications, but we know that there are better ones on the way.

Mike Roth: 9:51

You wanted to talk about vascular. Why don't you. go ahead and tell our listeners about that.

Dr. Craig Curtis: 9:57

Would love to. Thanks. So, I'll start with the question. Have you ever known someone who unfortunately had a heart attack or vascular disease, or maybe a stroke that seemed to be a little bit early?

Mike Roth: 10:08

Sure. A lot of people here in The Villages,

Dr. Craig Curtis: 10:10

So when we talk about the causes of heart attacks and strokes and peripheral vascular disease, we all know about things such as diabetes and smoking and poor diet choices. Those are all called modifiable risk factors. So you can change those and you can lower your risk. And then if we talk about non-modifiable risk factors, things you cannot change. There's a cholesterol that has been labeled the ghost cholesterol.

Mike Roth: 10:44

Well, I've heard of good cholesterol and bad cholesterol. Now I have to worry about a ghost cholesterol.

Dr. Craig Curtis: 10:51

That's right. So there's a cholesterol called. LP little A, otherwise known as lipoprotein A, and that cholesterol has been known about for a long time. However, scientists over the last decade have discovered that this is one of the major risk factors for heart disease, cardiovascular disease, cerebral vascular disease, such as strokes and peripheral vascular disease, such as problems in the legs. And what they've discovered is that this is a genetically linked lipoprotein.

Mike Roth: 11:28

It runs in families,

Dr. Craig Curtis: 11:30

it runs in families. Yes, it does. And unfortunately we've had no way to modify this. So what we've discovered is that people with high values will have about a six times higher risk of having heart disease, cerebrovascular disease such as strokes And this ghost cholesterol. We've had a blood test for a while, about 15 years that can detect it. And what we told people is if your cardiologist checked this and your value was high, they would just modify your modifiable risk factors. They would say, well, it looks like your very high risk for potential heart attacks or strokes, so let's lower your cholesterol, Bad cholesterol, down as low as we can. Please stop smoking if you're a smoker. Engage in diet and exercise other healthy habits to try to make your modifiable risk factors as good as they can be because there was nothing we could do about this, about your genetics. And unfortunately, the fact that you might have a high lipoprotein a. What's exciting is now we're studying a medication, a pill actually that lowers lipoprotein a by around 85%.

Mike Roth: 12:44

Wow. That's a big drop.

Dr. Craig Curtis: 12:45

It's a huge drop and this study was published about a year ago, and this was a small study with only around 500 people. That lasted about one year. Now that we know we can successfully lower lipoprotein A, we're moving on to a huge global study in 26 countries involving 13,000 people with elevated lipoprotein A. So we're going to screen about 100,000 people across the world for this. Because only about one in five, one in eight will have a high enough level of lipoprotein A for the clinical research study. And if we find someone with the very high value, they'll go on the medication. Or on placebo for five years, and it's called an outcome study. We're actually gonna follow these people to see if reducing LP little A or lipoprotein A actually reduces their risk of having a major adverse cardiac event.

Mike Roth: 13:48

It's gonna be a big double blind study.

Dr. Craig Curtis: 13:49

Big double blind study. Very, very important. It's probably one of the greatest advancements in the last 40 years in cardiology because we've all known people who have had early heart disease or had vascular problems, had carotid problems, blockages in their carotid arteries, and this occurred in people that. Did not smoke that did not have diabetes, and we really never knew why. For the longest time we just thought, oh, poor genetics and there was nothing we could do. And now really keying in on this, lipoprotein a, I think is going to be the next very, very important medical breakthrough in cardiology and reducing vascular disease, which. Ties into Alzheimer's disease. About 2020 5% of patients with Alzheimer's disease have some hardening of the arteries in the brain. Some slight, maybe mild to moderate vascular disease in the brain. We don't think necessarily that causes Alzheimer's disease, but we think it can make Alzheimer's disease worse. So therefore, if we find a way to improve their vascular. What we call endothelium, which is their blood vessels, essentially. Then maybe you can slow the course of Alzheimer's disease or slow the course of Parkinson's disease. If the rest of the blood vessels in the brain can be that much healthier, especially if it's due to elevated lipoprotein A.

Mike Roth: 15:17

Right. So with someone who wasn't in the study, we're going on a vegetarian diet. caused that lipoprotein A to go down.

Dr. Craig Curtis: 15:26

No, unfortunately diet has no effect on lipoprotein a. Wow. Right. this is a non-modifiable risk factor. Statins do not drop lipoprotein A to any significant effect. Now the new. Medicines that have come out for statins, they call 'em PCSK nine inhibitors Mm-hmm. long term, but those medications do drop. Lipoprotein A levels around 20%, so not very much. And it's a very expensive and time consuming way to lower lipoprotein a around 20%. So those medicines are not currently approved to lower lipoprotein A. They're just not very effective. They do a little bit. So diet doesn't, you cannot lower this via diet, via exercise Complete vegan or healthy diet. So yeah, that's why this is so important to finally have a pill that could potentially lower lipoprotein a. So this study's gonna take a few years. It's gonna take us the next probably six years to get the study done. But, the good news is we're offering that test to people. They can come and get a blood test. If they have risk factors, they have to have three risk factors.

Mike Roth: 16:44

What are the three risk factors.

Dr. Craig Curtis: 16:46

Well, there's a long list of factors, but three of the most common would be over the age of 65.

Mike Roth: 16:53

Mm-hmm.

Dr. Craig Curtis: 16:53

Have diabetes or high blood pressure on treatment or high cholesterol on treatment Diabetes with poor kidney function would be another one. So we are looking for people with risk factors. And they do need to have a couple of risk factors in order to get into the clinical trial or get the blood test.

Mike Roth: 17:13

That's a little unusual. looking For people who are much sicker. Than normal.

Dr. Craig Curtis: 17:17

Well, we need to do that because they're at higher risk of having a cardiac event in the next five years. The trial needs to, we can't run a trial forever because we'll have too many people dropping out and it will lead to an ineffective trial design. So in order to set a five year window for the trial, we do need people that are at risk of having a cardiac event because that will help us figure out if those on the drug have less cardiac events than those on placebo who might have more cardiac events. That's unfortunately the only way we can do the research study.

Mike Roth: 17:55

Good. Let me ask you a couple of questions. Dr. Curtis, There's been a lot of talk about hyperbaric oxygen helping the brain. What's your opinion on that?

Dr. Craig Curtis: 18:06

I actually have a very favorable opinion on that. I think that hyperbaric oxygen, the data looks good behind hyperbaric oxygen as far as for helping the brain that might need some help that might, you might have a condition such as a stroke or other neurological condition. What I don't have is a double-blind placebo controlled study showing two identical groups and statistically powered to show outcome. But the concept to me and the science to me seems like it's good science. I just don't have a double blind study to really base a full opinion on at this time.

Mike Roth: 18:46

Because there are three outfits here in The Villages offering

Dr. Craig Curtis: 18:49

three,

Mike Roth: 18:49

three,

Dr. Craig Curtis: 18:49

wow. Well, because the science is good behind it.

Mike Roth: 18:53

Mm-hmm.

Dr. Craig Curtis: 18:54

And there are good case studies behind it. the problem is We need a double blind placebo controlled decently long term study.

Mike Roth: 19:03

There were a couple of other things that are kicking around here. One is stem cells. What is your opinion of stem cells?

Dr. Craig Curtis: 19:09

My opinion on stem cells are that. Once again, I think the data, the science behind stem cells looks promising. There have been studies in mice using stem cells that also appear promising, but we don't have large, randomized double-blind placebo controlled trials in stem cells, so therefore. I think that it's a potential promising future for stem cells, but we don't know how much to give and where to give. So it's going to take a few more years. This science takes a long time to get done.

Mike Roth: 19:46

Mm-hmm. And there are other practitioners offering peptides.

Dr. Craig Curtis: 19:50

Yeah.

Mike Roth: 19:51

Administration patches.

Dr. Craig Curtis: 19:53

Yeah. Once again, we just don't have any double-blind placebo controlled trials on peptides as well. And a lot of these things can appear to be effective for a short while. And then we see in the long term that they actually. Did not do any good. I'm not saying they're not, because I don't know. I'm not an expert in that area, but I'm excited for the future for what we are looking at though,

Mike Roth: 20:21

right? There's a lot of anecdotal stories that show success. And I've also heard anecdotal stories of people who say, didn't work for me. And the same thing is true for blood rich plasma transfusions there.

Dr. Craig Curtis: 20:35

Platelet rich plasma. Sure. Yeah. That also sounds promising. Take Out of the blood, spin the blood down, use the pro-growth proteins, et cetera, and inject that into an arthritic joint or something. And it seems very plausible, but that it seems to be falling by the wayside. The PRP, the studies I don't think really support the use. They have done some double-blind studies. They have, and I think that we're, I haven't looked at that. I would like to see if there's been anything done with that recently. 'cause they did look at that in some double blind studies and I think they, it was essentially not really any different than placebo at the end of the day.

Mike Roth: 21:15

Yeah, I heard that from several people. That claimed didn't work.

Dr. Craig Curtis: 21:19

and you know, go back 10 years and people were, that's all they were talking about was PRP

Mike Roth: 21:24

mm-hmm.

Dr. Craig Curtis: 21:25

And, Yes, unfortunately science takes decades sometimes to figure things out. I know we don't have decades

Mike Roth: 21:30

Well, people are looking for a, a cure today, right? And people have been Told that stem cells injected into your knee will do better than a cortisone shot.

Dr. Craig Curtis: 21:40

Well, the FDA has not approved it for a reason and we're still waiting.

Mike Roth: 21:44

Yeah. The FDA rules seem to be very strict and that the Stem cells from a donated placenta from a woman can only be used if the woman never took a COVID shot because of the RNA.

Dr. Craig Curtis: 22:00

Really?

Mike Roth: 22:01

Yes.

Dr. Craig Curtis: 22:01

Did not know that.

Mike Roth: 22:03

Oh,

Dr. Craig Curtis: 22:03

wow. I know there's a company in Orlando that they're involved in harvesting stem cells and selling mostly out of the country, I believe.

Mike Roth: 22:13

Yeah, well that's another problem. In terms of chain of custody, you know, how do you know where those stem cells came from? Were they from a goat or, yeah. When it harvested from a placenta, well, you know, that couldn't have come from me, but it was it a goat or a human. was that human being ever administered an RNA vaccine for COVID?

Dr. Craig Curtis: 22:33

Well, I'm not sure I agree with that. You know, Mr. RNA should. Stay in the system. to my knowledge, it doesn't interfere with DNA, but I'm not an expert in that field, so I'll hold comment on that.

Mike Roth: 22:47

Okay. Yeah, there are three hyperbaric chambers here

Dr. Craig Curtis: 22:51

Three.

Mike Roth: 22:52

Yes.

Dr. Craig Curtis: 22:53

there was just one.

Mike Roth: 22:54

Avi has the best one.

Dr. Craig Curtis: 22:56

Yeah.

Mike Roth: 22:56

There's the wound care center. up in Lady Lake.

Dr. Craig Curtis: 22:59

Well, so that is FDA approved for diabetic wounds? Yeah, so that's why I like the science behind it. It definitely works. it heals wounds faster.

Mike Roth: 23:08

Well, that's one of the problems that in the anecdotal evidence, no double blind study, but I ran into a friend who was having a wound, and he was saying to me that it wasn't working.

Dr. Craig Curtis: 23:21

I thought that it did work and it was part of wound treatment, standard wound treatment. I could be wrong, but I thought it was,

Mike Roth: 23:27

yeah, I didn't know the whole story behind it. just caught it in a brief part of a conversation. The third one is a new center on 44 here called Sozo. They have a four person hyperbaric chamber. That actually is a very low cost compared to Avi. Oh, yeah. You know, like 10% of Avi cost. I understand they're about 55,000.

Dr. Craig Curtis: 23:50

I have no idea.

Mike Roth: 23:51

guys are about 4,000.

Dr. Craig Curtis: 23:53

You're kidding.

Mike Roth: 23:54

No, no. I mean I actually went over last week and sat in the chamber.

Dr. Craig Curtis: 23:58

What'd you think?

Mike Roth: 23:59

Well, it was a big, big metal tube It had four comfortable chairs in it. They only have one and they have one technician that operating it. But it seemed as safe as the AVI Chamber. Yeah. Certainly not as luxurious. Yeah. But you're only gonna be in there for an hour at a time.

Dr. Craig Curtis: 24:16

Yeah. I just wish we knew how much time and how long you should spend in there. I wish we knew those answers. That would be really nice to know.

Mike Roth: 24:25

Right. And I do know one avi patient who was there about a year and a half ago who did get better and it is now getting worse again.

Dr. Craig Curtis: 24:36

Yeah.

Mike Roth: 24:36

I think there's some additional follow on treatment with hyperbaric oxygen that has to be. A regimen, Maybe not like insulin where you have to take it every day.

Dr. Craig Curtis: 24:47

Well, maybe so.

Mike Roth: 24:48

Well,

Dr. Craig Curtis: 24:49

I mean, if you could do it,

Mike Roth: 24:50

Gimme a quick shot of oxygen Yeah.

Dr. Craig Curtis: 24:52

Every day

Mike Roth: 24:53

well, for the rest of your life.

Dr. Craig Curtis: 24:54

Yeah. For the rest of your life.

Mike Roth: 24:55

But if that kept your brain healthy. Yeah. There have been some studies that people have talked about using GLP one drugs to help Alzheimer's. what's the story on that?

Dr. Craig Curtis: 25:05

So, that was breaking news a few months ago. They released the results that showed, it was not a positive study, which means there was no statistical difference between the placebo group and those that received GLP ones for the length of the trial, which was approximately two years. Now, what they did find is that those, on the GLP ones did have trending biomarkers. The levels of tau and amyloid seemed to be moving in the right direction, so it's possible they didn't receive the treatment long enough. Maybe a two year trial was not enough, sort of what we just referenced in hyperbaric oxygen. Maybe you need it for a longer amount of time.

Mike Roth: 25:51

Yeah, longer than Three

Dr. Craig Curtis: 25:53

Longer than three months. So there's going to be more data released at a big meeting coming up in Copenhagen in March that I'll be attending called the Alzheimer's PD International Parkinson's Disease International Meeting. And they're going to release more information about the biomarkers in that study and whether or not they will do more. So stay tuned. I don't think they quite have. Answer yet, but the overall study was a failure. if you wanna look at it from a totality or the study in full.

Mike Roth: 26:25

But The study kind of indicates from what you're saying, that they need an additional study to go beyond two years.

Dr. Craig Curtis: 26:31

And those studies are very expensive. $400 million. So we'll see if they're willing to do it. So many people are on GLP ones nowadays. It's probably getting harder to find people to enter a study like that, that are naive to GLP ones.

Mike Roth: 26:47

Yeah. I know I'm not in favor of GLP once it's that. side effect that you can go blind on it.

Dr. Craig Curtis: 26:54

Rare. But it does appear that there's a little something to keep our eyes on. Get it.

Mike Roth: 26:59

but bomb, Keep our eye on,

Dr. Craig Curtis: 27:00

our eye on, yeah.

Mike Roth: 27:02

Yes. This isn't a comedy podcast, but just in case. This podcast was listed as number 15 on the Florida Po Comedy podcast list.

Dr. Craig Curtis: 27:11

Really?

Mike Roth: 27:11

we have had a few comedy podcasts. in the batch. But I was very surprised. at. that.

Dr. Craig Curtis: 27:17

To laugh. Comedy's good for you.

Mike Roth: 27:19

That's right, so is there anything else you want to add, Dr. Curtis?

Dr. Craig Curtis: 27:22

No, thank you for having me today. That was a very wonderful to be here and to share some news on the vascular front and on the Alzheimer's front. So thank you very much.

Mike Roth: 27:32

Dr. Curtis. If someone wants to contact Your firm, K two Medical research, how do they do that?

Dr. Craig Curtis: 27:38

Well, we're right here in The Villages in Lady Lake, and our office number is 3 5 2 500 52 5 2.

Mike Roth: 27:46

Okay, and is there a website that can go to?

Dr. Craig Curtis: 27:49

There is k2medicalmesearch.com.

Mike Roth: 27:52

And how many new studies do you think you're going to undertake this year?

Dr. Craig Curtis: 27:56

Approximately six to seven new studies this year. The vascular and the cardiometabolic space is really big and that's important for us. That encompasses a lot of different diseases.

Mike Roth: 28:10

I know when we first talked, you said you don't have any overnight patients or overnight studies. Has that changed?

Dr. Craig Curtis: 28:16

Well, we do have one for Alzheimer's and one for Parkinson's currently, but those are only a single overnight study. But those are early studies looking at the way these medications work they're called phase one studies.

Mike Roth: 28:30

Ah, okay. Good. Thanks very much Dr. Curtis.

Dr. Craig Curtis: 28:33

Thank you, Mike.

Dolores (2): 28:34

Remember, our next episode will be released next Friday at 9:00 AM Should you wanna become a major supporter of the show or have questions, please contact us at mike@rothvoice.com. This is a shout out for supporters, Tweet Coleman, Ed Williams, Duane Roemmich, Paul Sorgen, and Dr. Craig Curtis at K 2 in The Villages. We will be hearing more from Dr. Curtis with short Alzheimer's tips each week. If you know someone who should be on the show, contact us at Mike at RothVoice.com. Use the "FAN MAIL" button on our home page "VillagesVitality.Life" to leave comments, be sure to include your name, email and phone number. The way our show grows is with your help. Text your friends about this show, if you enjoyed listening. The content of the show is copyrighted by Roth Voice 2026, all rights reserved.